title: Single center experience of treatment of Ewing's family of tumors in Japan.
abstract: BACKGROUND
  Japanese patients with the Ewing's family of tumors (EFTs) reportedly have a worse prognosis than their European Caucasian counterparts. However, details of the prognosis of Japanese EFT patients have not been clearly defined because of the lack of representative clinical studies of the results of contemporary, multidisciplinary treatments.
  
  
  METHODS
  The present study analyzed the outcome of 19 consecutive patients with EFTs who were treated with a multidisciplinary approach at a single institution. Combination chemotherapy consisting of vincristine, actinomycin D, Adriamycin (doxorubicin), and ifosfamide was administered as induction chemotherapy. Local therapy was administered individually, considering various factors, with the ultimate aim of complete surgical resection. Nine patients who satisfied the inclusion criteria received high-dose chemotherapy with peripheral blood stem cell rescue as a consolidation treatment.
  
  
  RESULTS
  The 3-year overall and event-free survival rates were 62% and 51%, respectively, which were comparable to results from Western countries, although the number of subjects was too small to allow definitive conclusions to be drawn.
  
  
  CONCLUSIONS
  There is a clear need to investigate the results of treatment of Japanese EFT patients in a multiinstitutional, prospective clinical study.
authors.affiliation: Department of Orthopaedics, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya, 464-8681, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamada
authors.forename: Hideshi
authors.initials: H
authors.lastname: Sugiura
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Takahashi
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D011379:Prognosis; D011446:Prospective Studies; D018570:Risk Assessment; D012512:Sarcoma, Ewing / Q000453:epidemiology / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome